DexCom, Inc. (NASDAQ:DXCM) has been the object of insider selling activity recently. Kevin R. Sayer, President & CEO disclosed the sale of 6,000 shares of DXCM stock. The shares were purchased at an average price of $71.86. The President & CEO now owns $23,475,225 of the stock according to the SEC filing. Andrew K. Balo, EVP, Reg. Strategy, Clinical sold $228,960 worth of shares at an average price of $71.55 on Mon the 10th. Balo now owns $7,386,321 of stock as reported to the SEC.
Richard Doubleday, EVP sold $249,287 worth of shares at an average price of $78.22 on Fri the 23rd. That brings Doubleday’s holdings to $1,988,352 per an SEC filing yesterday.
Dexcom, Inc. (Dexcom), launched on May 13, 1999, is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Business’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system..
Here are a few other firms who have also updated their positions. As of quarter end Creative Planning had bought a total of 92 shares growing its stake by 24.2%. The value of the investment in DexCom, Inc. went from $32,000 to $35,000 increasing 9.4% quarter to quarter. As of the end of the quarter Rhenman & Partners Asset Management Ab had acquired 47,480 shares growing its holdings by 83.4%. The value of the total investment in DexCom, Inc. increased from $4,821,000 to $7,635,000 a change of 58.4% quarter over quarter.
As of the end of the quarter Handelsbanken Fonder Ab had bought 11,500 shares growing its position 115.0%. The value of the company’s investment in DexCom, Inc. increased from $847,000 to $1,573,000 a change of $726,000 since the last quarter. Xact Kapitalforvaltning Ab bolstered its investment by buying 250 shares an increase of 2.3% as of 06/30/2017. Xact Kapitalforvaltning Ab now holds 10,954 shares with a value of $801,000. The value of the position overall is down by 11.7%.
On December 15 the stock rating was upgraded to “Buy” from “Neutral” by B. Riley. On October 31, 2016 the stock rating was rated “Buy” according to a BTIG Research report a boost from the previous “Neutral” rating.
B. Riley starting coverage on the stock by announcing an initial rating of “Neutral” and establishing a price target of $97.00. On September 16 the company was changed to a “Buy” in a report from Desjardins which is up from the previous “” rating.
On September 14 the company was downgraded from “Buy” to “Neutral” in an announcement from BTIG Research. On April 14, 2016 BTIG Research added DXCM to its research portfolio setting a rating of “Buy” and projecting a price target of $80.00.
The company is so far trading up from yesterday’s close of $71.49. The stock is trading at $71.79 barely above $71.68, the 50 day moving average and which is just under the 200 day moving average of $74.65. The 50 day moving average was up $0.11 or +0.15% whereas the 200 day average was down by -3.83%.
In the latest earnings report the EPS was $-1.04 and is projected to be $-0.70 for the current year with 86,369,000 shares presently outstanding. Next quarter’s EPS is expected be $-0.09 and the next full year EPS is anticipated to be $0.01.Advertisement